Vactosertib, a Novel Transforming Growth Factor Beta (TGFβ) Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness: A Single-Arm, Phase Ib Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Malek, Ehsan [1 ,2 ]
Rana, Priyanka [1 ,2 ]
Daunov, Michael [1 ,2 ]
Miyagi, Masaru [1 ,2 ]
Ignatz-Hoover, James [1 ,2 ]
Metheny, Leland [1 ,2 ]
Driscoll, James [1 ,2 ]
机构：
[1] Univ Hosp Cleveland, Div Hematol Oncol, Cleveland, OH 44106 USA
[2] Case Comprehens Canc Ctr, Cleveland, OH USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
multiple myeloma (MM); transforming growth factor beta (TGFb) receptor kinase inhibitor; cytotoxic T lymphocyte; immunosuppression; T-cell fitness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-514
引用
收藏
页码：S505 / S506
页数：2
相关论文
共 23 条
  • [1] Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma
    Malek, Esan
    Rana, Priyanka S.
    Swamydas, Muthulekha
    Daunov, Michael
    Miyagi, Masaru
    Murphy, Elena
    Ignatz-Hoover, James J.
    Metheny, Leland
    Kim, Seong-Jin
    James, Driscoll J., II
    BLOOD, 2023, 142
  • [2] The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial
    Malek, Ehsan
    Ignatz-Hoover, James J.
    Rana, Priyanka S.
    Driscoll Ii, James J.
    BLOOD, 2024, 144 : 7042 - 7042
  • [3] The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial
    Malek, Ehsan
    Rana, Priyanka S.
    Swamydas, Muthulekha
    Daunov, Michael
    Miyagi, Masaru
    Murphy, Elena
    Ignatz-Hoover, James J.
    Metheny, Leland
    Kim, Seong Jin
    Driscoll, James J.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [4] A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
    Huangming Hong
    Zegeng Chen
    Mingzhi Zhang
    Zhigang Peng
    Jianzhen Shen
    Yuerong Shuang
    Hui Zhou
    Hongqiang Guo
    He Huang
    Fei Li
    Zhengzi Qian
    Lihong Liu
    Liang Wang
    Wei Yang
    Liling Zhang
    Pengcheng He
    Shen Qian
    Fugen Li
    Meng Li
    Tongyu Lin
    Journal of Hematology & Oncology, 18 (1)
  • [5] A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
    Hong, Huangming
    Zhang, Mingzhi
    Peng, Zhigang
    Shen, Jianzhen
    Shuang, Yuerong
    Zhou, Hui
    Guo, Hongqiang
    Huang, He
    Li, Fei
    Qian, Zhengzi
    Liu, Lihong
    Wang, Liang
    Yang, Wei
    Zhang, Liling
    He, Pengcheng
    Qian, Shen
    Li, Fugen
    Li, Meng
    Lin, Tongyu
    BLOOD, 2023, 142
  • [6] MP0250-a dual inhibitor of VEGF and HGF - plus bortezomib plus dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM)
    Raab, M. S.
    Ria, R.
    Schlenzka, J.
    Krahnke, T.
    Haunschild, J.
    Herrmann, F.
    Fiedler, U.
    Dawson, K.
    Stumpp, M. T.
    Mehr, K. Tadjalli
    Harstrick, A.
    Vacca, A.
    Goldschmidt, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-inhuman trial
    Cowan, Andrew J.
    Pont, Margot J.
    Sather, Blythe
    Turtle, Cameron J.
    Till, Brian G.
    Libby, Edward N.
    Coffey, David G.
    Tuazon, Sherilyn A.
    Wood, Brent
    Gooley, Ted
    Wu, Vicky Q.
    Voutsinas, Jenna
    Song, Xiaoling
    Shadman, Mazyar
    Gauthier, Jordan
    Chapuis, Aude G.
    Milano, Filippo
    Maloney, David G.
    Riddell, Stanley R.
    Green, Damian J.
    LANCET ONCOLOGY, 2023, 24 (07): : 811 - 822
  • [8] Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial
    Xia, Jieyun
    Li, Hujun
    Yan, Zhiling
    Zhou, Dian
    Wang, Ying
    Qi, Yuekun
    Cao, Jiang
    Li, Depeng
    Cheng, Hai
    Sang, Wei
    Zhu, Feng
    Sun, Haiying
    Chen, Wei
    Qi, Kunming
    Yan, Dongmei
    Qiu, Tingting
    Qiao, Jianlin
    Yao, Ruosi
    Liu, Yang
    Wang, Xue
    Zhang, Yanlei
    Peng, Shuixiu
    Huang, Chih-Hua
    Zheng, Junnian
    Li, Zhenyu
    Chang, Alex H. H.
    Xu, Kailin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2583 - +
  • [9] SKI2162, A NOVEL TRANSFORMING GROWTH FACTOR (TGF)-BETA TYPE I RECEPTOR KINASE (ALK5) INHIBITOR, ALLEVIATES PROFIBROTIC TGF-BETA1 RESPONSES IN FIBROBLASTS DERIVED FROM PEYRONIE'S PLAQUE
    Ryu, J. K.
    Piao, S.
    Choi, M. J.
    Tumurbaatar, M.
    Kim, W. J.
    Jin, H. R.
    Shin, S. H.
    Yim, G. N.
    Song, J. S.
    Kwon, M. H.
    Song, K. M.
    Suh, J. K.
    Song, Y. S.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 155 - 155
  • [10] Preliminary results of a phase I trial inspire the phase II KarMMa study of bb2121, an anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell therapy, for relapsed and refractory Multiple Myeloma (rrMM)
    Einsele, H.
    Goldschmidt, H.
    Weisel, K.
    Hege, K.
    Munshi, N.
    San Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 134 - 134
123